New alliance aims to improve early-stage candidate profiling and accelerate drug development.

Landmark BioVentures (LBV) and G.CLIPS Biotech have formalized a strategic alliance to address one of early drug development’s most persistent challenges: poor target engagement and inadequate candidate profiling.

The companies, which began working together in 2023, announced the expanded collaboration yesterday (April 23). While financial details were not disclosed, both parties said the partnership strengthens their shared commitment to integrating conformation-sensitive and pathology-sensitive data into early discovery efforts—an area often limited by technical and financial barriers.

“Target engagement isn’t just a box to check; it is the cornerstone of successful drug development,” said Zaki Sellam, co-founder and CEO of LBV.

“This strategic alliance with G.CLIPS equips our nexus of companies with tools that were previously inaccessible, turning a traditional bottleneck into a strategic advantage.”

Deepening collaboration to de-risk drug development

The partnership builds on validation work already completed by LBV, which confirmed that G.CLIPS’ platform could provide novel, cost-effective approaches to profiling drug candidates and engaging difficult targets.

The two companies say early integration of this approach helps de-risk therapeutic development—delivering efficiencies in both time and cost, and ultimately improving the likelihood of clinical success.

“By embedding G.CLIPS within our innovation ecosystem, we can now more effectively support lead candidate nomination, understand specific mechanisms of action, and define the target product profile with greater precision,” Sellam added.

G.CLIPS Biotech, a platform company focused on conformation- and pathology-sensitive target engagement, said the alliance gives it a broader role within LBV’s network of biotech companies.

“We’re excited to deploy our unique technology platform across LBV’s nexus through this alliance,” said Rosie Dawaliby, co-founder and CEO at G.CLIPS Biotech.

“LBV’s integrative model aligns perfectly with our approach, allowing us to demonstrate G.CLIPS’ value as an embedded strategic partner in drug development programs.”

The companies described the collaboration as a response to growing industry recognition that successful therapeutic development depends not just on identifying promising targets, but on confirming that candidates are truly engaging those targets in disease-relevant ways. They believe this alliance could provide a new framework for closing the gap between discovery and clinical readiness.